CClinicalTrials.gg
Status unknownNCT03793075Updated Jan 7, 2019

Ketamine Versus Propofol Effect on the Immune-mediatory Response for Abdominal Surgery

An interventional study of Ketamine and Propofol in Major Abdominal Surgery, sponsored by Mansoura University Hospital. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Mansoura University Hospital · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Host systemic responses to vigorous stimuli as trauma, surgical tissue injury, anesthesia and post-operative pain, leads to release a variety of pro-inflammatory cytokines including interleukin-1 (IL-1) and interleukin-6 (IL-6) mainly from monocytes and macrophages Thus, the rise of IL-6 is regarded as an early marker of tissue damage and its rise proportional to the degree of tissue damage .

It has been demonstrated that systemic responses to stress may be modified by the anesthetic technique used . Total intravenous anesthesia (TIVA) especially propofol based greatly suppresses the stress response induced by surgery when compared to inhalation by lowering cortisol levels.

Ketamine has the ability to modulate (modify) inflammation . Even the sub-anesthetic doses of ketamine in animal models were even provided to have an effect on the inflammatory response system in the central nervous system

Read the detailed description

The release a variety of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6) mainly from monocytes and macrophages due to surgical trauma or anesthesia .

IL-6 is constantly found in the peripheral blood and rapidly within few minutes unlike other pro inflammatory mediators. Thus, the rise of IL-6 is regarded as an early marker of tissue damage and IL-6 levels are proportional to the degree of tissue damage . The two major actions of IL-6 are having a key role in regulating stress responses by activating the hypothalamic-pituitary- adrenal (HPA) axis and synthesizing fibrinogen (which is necessary for the acute-phase response) serving as a growth factor for activated B-cells .

While appropriate inflammatory reactions are advantageous and essential for wound healing and host defense against microorganisms, excessive immune responses can be detrimental. The released mediators prompt systemic endocrine, immunological and metabolic responses result in increased pain sensitivity, altered metabolism, hyperthermia and greater secretion of liver acute phase proteins and stress hormones, so yields unstable patient's hemodynamic status

Propofol was documented to have an advantage in terms of inflammatory and immunomodulatory effects through significant effect on TNF-α, IL-6 and IL-10 release .

Ketamine has the ability to modulate (modify) inflammation and this is why it is recommended in patients with sepsis undergoing surgery . This may be possibly related with the variations in TNF-α and nuclear factor-κB expression . Even the sub-anesthetic doses of ketamine in animal models were even provided to have an effect on the inflammatory response system in the central nervous system which is involved in its therapeutic effect on depression (Yang-2 et al., 2013).

This study will be conducted to compare between the intravenous infusion of ketamine against the intravenous infusion of propofol during general anesthesia in patients undergoing major abdominal surgeries.

02

Conditions studied

  • Major Abdominal Surgery
03

In context

Lead sponsor

Mansoura University Hospital is the lead sponsor of 50 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Elective major abdominal surgeries with median incision with right or left extension.
  • ASA -physical status I -II
  • aged from 18 till 70 years

Exclusion criteria

Exclusion Criteria:

  • body mass index more than 35 kg/m2,
  • Patients having severe cardiovascular, respiratory, hepatic, renal, Endocrinol disorders, malignant
  • Patients having chronic inflammatory diseases
  • Patients received suppressant drugs in the 6 weeks before surgery.
  • Any known allergy or any contraindications to anesthetic drugs;
  • patient refusal,
  • The usage of anti- emetic drug 24 hours before operation
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
36 participants (estimated)

Study arms

  • Placebo comparator
    Propofol group (P)

    The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings

    Drug: Propofol

  • Active comparator
    Ketamine group ((K)

    The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings

    Drug: Ketamine

Interventions

  • DrugKetamine

    ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion

    Also known as: ketalar

  • DrugPropofol

    propofol 17 mcg /kg/min

    Also known as: diprivan

06

What researchers measure

Primary outcomes

  1. Serum level of interleukin 6 (IL-6)

    picogram/milliliter using ELISA techniques .Five measurement points : before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before the induction of anesthesia till the first 24 hours postoperative

  2. Serum level of interleukin IL-1β (IL-1β)

    picogram/milliliter using ELSA techniques .Five measurement points : before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

Secondary outcomes

  1. Absolute neutrophil count

    Number multiplied by 1000/micro liter,measured before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

  2. Total leukocyte count

    Number multiplied by 1000/micro liter ,measured before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

  3. Neutrophil-lymphocyte ratio (N/L ratio)

    measured before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

  4. Serum Cortisol level

    micro-gram /deciliter by immunoassays techniques.measured before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

  5. C-reactive protein serum level

    milgram/liter using ELISA technique. measured before the induction of general anesthesia, 30 min after beginning infusion of the anesthetic agent , then 2h, 8h and 24 hours postoperative.

    Time frame: The time frame extend from 10 minutes before induction of anesthesia till the first 24 hours postoperative

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03793075
Lead sponsor
Mansoura University Hospital
Responsible party
Abdelraouf Elsharkawy (Lecturer of anesthesia and surgical intensive care, Mansoura University Hospital) — Principal investigator
First posted
Jan 4, 2019
Start date
Jan 10, 2019 (estimated)
Primary completion
Jun 1, 2019 (estimated)
Completion
Aug 15, 2019 (estimated)
Last update
Jan 7, 2019

Study contacts

Reem Abdelraouf, lecturer
Contact
reemraouf64@gmail.com
01006151100
Reem Abdelraouf, lecturer
principal investigator · Mansoura University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion